CCT244747

CCT244747

C655639-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

CCT244747 is a potent, orally bioavailable and highly selective CHK1 inhibitor, with an IC 50 of 7.7 nM; CCT244747 also abrogates G2 checkpoint with an IC 50 of 29 nM. In Vitro CCT244747 poorly inhibits CHK2 (IC 50 >10 μM) and CDK1 (IC 50 >10 μM). CCT244747 has potent activities against CHK1, RSK1, RSK2, AMPK, BRSK1, IRAK1,and TrkA, with >80% inhibition. CCT244747 (10 μM) exhibits In Vivo CCT244747 (100 mg/kg po, qd7d) significantly reduces tumor burden in human tumor xenografts. CCT244747 (100-300 mg/kg, po) inhibits gemcitabine-induced pS296 CHK1 for up to 24 h in HT29 colon tumor xenografts . CCT244747 (75 mg/kg, p.o.) in combination with gemcitabine has potent antitumor effects in HT29 colon tumor xenografts and Calu6 human lung cancer xenografts. CCT244747 (150 mg/kg p.o.) also shows antitumor activities with irinotecan in SW620 human colon tumor xenografts. CCT244747 (100 mg/kg, p.o.) exhibits radiosensitization activity in Cal27 xenografts. MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:Chk1 7.7 nM (IC 50 )

CCT244747 是一种强效、可口服的高选择性 CHK1 抑制剂，其 IC 50 为 7.7 nM；CCT244747 还能减弱 G2 检查点，其 IC 50 为 29 nM。

1404095-34-6(DMSO)

C20H24N8O2

408.47 g/mol

CC(CN(C)C)OC1=NC(=CN=C1C#N)NC2=NC=C(C(=C2)OC)C3=CN(N=C3)C